Psilocybin vs. Ketamine: What's Actually Available?

Psychedelic medicine headlines are dominated by psilocybin — the active compound in "magic mushrooms" — while ketamine quietly does most of the actual clinical work. If you're deciding what's realistically available to you, the comparison mostly comes down to one word: legality. But the substances differ in interesting ways beyond that.

Legal status: the decisive difference

• Ketamine is FDA-approved medicine (as an anesthetic), legally prescribable off-label for mental health everywhere in the U.S., with hundreds of clinics operating openly and one FDA-approved form (Spravato) covered by insurance.
• Psilocybin remains federally Schedule I. Oregon and Colorado run state-licensed programs where adults can access facilitated psilocybin sessions at licensed centers — notably without requiring a diagnosis — and a growing list of cities has deprioritized enforcement. Everywhere else, legal access means enrolling in a clinical trial.

So for most Americans in 2026, the honest comparison isn't "which should I choose?" but "ketamine now, or travel/wait for psilocybin."

How the experiences differ

Both produce altered states, but they're qualitatively different:

• Ketamine (a dissociative anesthetic): a dreamlike, floaty detachment from body and surroundings lasting under an hour for IV sessions, with same-day recovery. See what a session feels like.
• Psilocybin (a classic psychedelic): a 4–6 hour journey with perceptual changes, emotional intensity, and often deeply personal or mystical-feeling content. The long duration is why licensed programs require a facilitator present throughout — and why a session is an all-day commitment.

Psilocybin experiences are typically more psychologically demanding; difficult passages during sessions are common even in successful treatments. Ketamine is shorter, more controllable (especially IV), and far easier to schedule into a life.

What the evidence says

• Ketamine: substantial evidence in treatment-resistant depression, with rapid effects and a well-understood need for maintenance dosing. Also studied in PTSD, anxiety, OCD, and chronic pain.
• Psilocybin: strong mid-stage trial results in depression — including trials suggesting one or two sessions can produce effects lasting months, a durability ketamine can't match. Promising data in end-of-life anxiety and alcohol use disorder. But large phase-3 programs are still completing, and FDA approval hasn't happened yet.

The durability contrast is real and worth noting: psilocybin's effects appear longer-lasting per session, while ketamine's advantage is being available, repeatable, and medically routine.

Cost and practical access

• Ketamine: $400–$800 per infusion, at-home programs from ~$150/month, Spravato via insurance. Bookable this week in most metro areas — find clinics near you.
• Psilocybin: Oregon and Colorado program sessions commonly run $1,000–$3,000+ all-in (preparation, facilitation, integration), never covered by insurance, and require travel for most people.

A word on doing neither legally

Underground psilocybin use for self-treatment is common and we'd be pretending not to know that. Without endorsing it: the licensed-program model exists because screening (for psychosis risk, bipolar disorder, and medication interactions) and a trained facilitator during a six-hour vulnerable state are genuine safety infrastructure, not bureaucracy. The same logic applies to ketamine — which is why clinic quality matters there too.

Bottom line

If you need help now, ketamine is the treatment that's actually available, legal, and clinically supported where you live. Psilocybin is a genuinely promising treatment with impressive durability data whose legal access remains limited to two states and clinical trials. Many clinicians expect them to end up as complementary tools; for now, the practical path for most people starts at a ketamine clinic — ideally one honest enough to tell you exactly this.